Clinical Trials Directory

Trials / Completed

CompletedNCT00724919

A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)

Status
Completed
Phase
Study type
Observational
Enrollment
256 (actual)
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres

Detailed description

This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.

Conditions

Timeline

Start date
2003-12-01
Primary completion
2004-04-01
Completion
2004-04-01
First posted
2008-07-30
Last updated
2008-08-11

Locations

2 sites across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT00724919. Inclusion in this directory is not an endorsement.

A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli (NCT00724919) · Clinical Trials Directory